Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2713)	3/19/2010 11:50:43 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

NMTI was up 5.77% and was trading at its intraday H when I started typing this note, but with some downticks is now up only 3.02% at present.<g> Volume of > 55Ks is already > its ADV. The stock has had a good % gain since the UT started in mid-Nov, and has doubled since the last wave started in Mid-Feb.(3rd Elliot ?) <g> bigcharts.marketwatch.com There is a good amount of resistance at the $5 level, but with some good news, the stock could get there, or even a little higher.<g> bigcharts.marketwatch.com The ACTAY is $3. Insiders reportedly hold 30% Bernard

To: Jibacoa who wrote (2713)	5/7/2010 10:54:15 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

RXII is up 9.14% bigcharts.marketwatch.com On Tuesday it announced preclinical data showing effective delivery of its sd-rxRNA to retinal cells in the mouse eye that demonstrate significant target gene silencing in vivo following local administration. In comparison, local injection of a more traditional RNA duplex results in negligible delivery. According to them, the next generation sd-rxRNA compounds will potentially provide significant advantages over conventional siRNA compounds, and offer many of the properties that will be important for the clinical development of RNAi-based drugs. ( I will have to get the opinion of some Ophthalmologists that I turst.on all these statements.<g>) "The advantages include high potency, increased resistance to nucleases and reduction in off-target effects. In addition, sd-rxRNA compounds provide additional unique properties in that they are able to enter cells and tissues with no requirement for any additional delivery vehicle." In spite of yesterday's dip, the stock seems to have support at the $4 level.<g> If it could get back to $6 it would be a nice % gain. bigcharts.marketwatch.com The March 2008 the H was $23.95 <g> bigcharts.marketwatch.com Bernard